论文部分内容阅读
通过对尿液总糖胺聚糖的含量测定，尿液原型古糖酯的检测以及尿液对一水草酸钙晶体生长和聚集抑制率的变化，研究大鼠一次性口服古糖酯（２００ｍ ｇ／ｋｇ）后，三天内尿液糖胺聚糖的变化，以及尿液对一水草酸钙晶体生长和聚集抑制率的变化。结果表明，大鼠口服古糖酯后，尿总糖胺聚糖含量在第一天和第二天显著升高，第三天恢复到原有水平。与之对应，尿原型古糖酯在第一、二天可以测到，第三天消失，尿液对一水草酸钙晶体聚集抑制活性显著增强，但对晶体的生长抑制没有显著增强作用。该实验部分提供了古糖酯的代谢结果，并为古糖酯作为尿路结石抑制剂提供了有力的实验证据。
The content of total glycosaminoglycans in urine, the detection of urinary archaic sugar esters, and the change of urinary calcium oxalate crystal growth and aggregation inhibition rate were investigated. / Kg), changes in urine glycosaminoglycans within three days, and changes in urinary inhibition of growth and aggregation of calcium oxalate monohydrate crystals. The results showed that after oral administration of the ancient sugar ester, the total glycosaminoglycan content in urine increased significantly on the first day and the second day, and returned to its original level on the third day. Correspondingly, the urinary prototype ancient sugar ester could be detected in the first and second days and disappeared on the third day. Urine significantly enhanced the aggregation inhibition activity of calcium oxalate monohydrate crystals, but did not significantly enhance the crystal growth inhibition. This experimental section provides the metabolic consequences of the ancient sugar esters and provides strong experimental evidence for the ancient sugar esters as urolithiasis inhibitors.